Dosing regimen for sedation with CNS 7056 (Remimazolam)
The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
1. A method of sedating a subject, comprising administering to the subject an initial dose of the besylate salt of 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-][1,4]benzodiazepin-4-yl]-propionic methyl ester of formula (I)
wherein the initial dose is a fixed dose of between about 2 mg and about 10 mg and is irrespective of the body weight of the subject.
2. The method of claim 1 , wherein the initial fixed dose of the besylate salt of the compound of formula (I) is selected from the group consisting of between about 3 mg and about 10 mg; between about 3 mg and about 9 mg; and between about 5 mg and about 8 mg.
3. The method of claim 1 , further comprising administering to the subject one or more subsequent doses of the besylate salt of the compound of formula (I), wherein the one or more subsequent doses are fixed doses, are irrespective of body weight, and are selected from the group consisting of between about 1 and about 4 mg; between about 1.5 mg and about 3.5 mg; and between about 2 and about 3 mg.
4. The method of claim 3 , wherein the initial fixed dose and the one or more subsequent fixed doses of the besylate salt of the compound of formula (I) administered to the subject are selected from the group consisting of:
a) about 8 mg of an initial fixed dose and about 3 mg of a subsequent fixed dose,
b) about 7 mg of an initial fixed dose and about 2 mg of a subsequent fixed dose, and
c) about 5 mg of an initial fixed dose and about 3 mg of a subsequent fixed dose.
5. The method of claim 3 , wherein the one or more subsequent fixed doses of the besylate salt of the compound of formula (I) is administered to the subject not earlier than 2 minutes from the time the initial fixed dose is administered to the subject.
6. The method of claim 3 , wherein not more than six subsequent fixed doses of the besylate salt of the compound of formula (I) are administered to the subject.
7. The method of claim 1 , wherein the besylate salt of the compound of formula (I) is administered to the subject intravenously.
8. A method of sedating a subject, comprising administering to the subject a dose of the besylate salt of 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]-propionic methyl ester of formula (I),
wherein the dose is a fixed dose of between about 2 mg and about 10 mg and is irrespective of the body weight of the subject.
9. The method of claim 8 , wherein the dose of the besylate salt of the compound of formula (I) is selected from the group consisting of between about 3 mg and about 10 mg; between about 3 mg and about 9 mg; and between about 5 mg and about 8 mg.
10. The method of claim 9 , wherein the dose of the besylate salt of the compound of formula (I) is about 5 mg.
11. The method of claim 8 , wherein the subject is undergoing an operative procedure.
12. The method of claim 11 , wherein the operative procedure is a diagnostic procedure.
13. The method of claim 12 , wherein the diagnostic procedure is an endoscopic procedure.
14. The method of claim 13 , wherein the endoscopic procedure is colonoscopy.
15. The method of claim 13 , wherein the endoscopic procedure is upper GI endoscopy.
16. The method of claim 11 , wherein the operative procedure is a therapeutic procedure.
17. The method of claim 8 , wherein the besylate salt of the compound formula (I) is administered to the subject intravenously.
18. The method of claim 17 , wherein the besylate salt of the compound of formula (I) is administered to the subject in the form of a saline solution.
19. The method of claim 17 , wherein the besylate salt of the compound of formula (I) is administered to the subject over 1 minute.
20. The method of claim 8 , wherein the besylate salt of the compound of formula (I) is administered to the subject at a dose of between about 5 mg to about 8 mg, and wherein the besylate salt of the compound of formula (I) is administered to the subject intravenously in the form of a saline solution over 1 minute.